Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07719920 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase Ia/Ib Study of HW221043 in Participants With Advanced Solid Tumors

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of Jul 30, 2026 to Sep 10, 2026 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Jul 30, 2026 to Sep 10, 2026
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase Ia/Ib, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and preliminary efficacy of HW221043 tablets in participants with advanced solid tumors. It includes two parts: the dose escalation study (Phase Ia) and the dose expansion study (Phase Ib).
Trial Details
NCT Number NCT07719920
Lead Sponsor Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Conditions Advanced Solid Tumors
Enrollment 99 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov